100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43ES029898
Award Date
5/15/19
Completion Date
6/14/20
Dollars Obligated
$225K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Institute of Environmental Health Sciences
Awardee
Stem Pharm, Incorporated (YTLQLAJ53CB7)
Federal Grant Program
93.113
Assistance Type
Project Grant
Place of Performance
Madison, WI 53711, USA
Update #1
Update #2
HYDROGEL-ENABLED SELF-ASSEMBLED HUMAN BRAIN ORGANOIDS FOR DEVELOPMENTAL NEUROTOXICITY APPLICATIONS
Posted 5/10/19
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
HYDROGEL-ENABLED SELF-ASSEMBLED HUMAN BRAIN ORGANOIDS FOR DEVELOPMENTAL NEUROTOXICITY APPLICATIONS - PROJECT SUMMARY/ABSTRACT THERE IS A WELL-RECOGNIZED NEED FOR MORE ACCURATE AND COST-EFFECTIVE TOXICOLOGY SCREENING FOR THERAPEUTIC AND ENVIRONMENTAL COMPOUNDS. CURRENT METHODS USING CELL CULTURES OR ANIMAL MODELS LACK PREDICTABILITY AND CAN BE COSTLY. RECENT ADVANCES IN THE DEVELOPMENT OF STEM-CELL DERIVED BRAIN-ORGANOIDS HAVE LED TO INCREASING INTEREST IN THESE MODELS FOR NEURAL TOXICOLOGY SCREENING AS WELL AS FOR DRUG SCREENING AND THE STUDY OF NEURAL DEVELOPMENTAL MECHANISMS. HOWEVER, BECAUSE OF THEIR COST, COMPLEXITY, AND WORKFLOW REQUIREMENTS, THESE METHODS HAVE YET TO BE EFFECTIVELY IMPLEMENTED BEYOND RESEARCH APPLICATIONS. CURRENTLY NEURAL ORGANOIDS ARE TYPICALLY FORMED ON A COMPLEX EXTRACELLULAR-MATRIX DERIVED FROM TUMORS CULTURED IN RODENTS (COMMONLY KNOWN AS MATRIGEL). THE PROCESS IS CUMBERSOME, MAKES INTERROGATION DIFFICULT, AND LACKS REPRODUCIBILITY. MORE RECENTLY, INVESTIGATORS, INCLUDING A STEM PHARM COFOUNDER, HAVE DEMONSTRATED THAT COMPLEX NEURAL ORGANOIDS CAN BE FORMED, CULTURED, AND ASSAYED REPRODUCIBLY IN A PLATE-BASED SYSTEM ON ENGINEERED HYDROGEL SUBSTRATES WITH HUMAN EMBRYONIC STEM (ES) CELL-DERIVED PRECURSOR CELLS. WORK IN THIS PROPOSAL WILL FURTHER THAT DEVELOPMENT AND LEAD TO THE VALIDATION OF AN IPSC-DERIVED NEURAL ORGANOID THAT CAN BE SELF-ASSEMBLED AND CULTURED ON STEM PHARM'S SPECIALIZED SYNTHETIC HYDROGEL IN A 96-WELL PLATE FORMAT THAT IS AMENABLE TO AUTOMATED SCREENING APPLICATIONS. SPECIFIC AIMS WILL 1) VALIDATE IPSC-DERIVED HUMAN NEURAL ORGANOIDS FORMED ON STEM PHARM SYNTHETIC HYDROGELS UTILIZING NEURAL PROGENITORS AS WELL AS VASCULAR AND MICROGLIAL CELLS; 2) TRANSITION THE ORGANOID FORMATION, GROWTH, AND INTERROGATION TO A 96-WELL PLATE FORMAT. THIS WILL REQUIRE EXPERIMENTATION AND OPTIMIZATION OF HYDROGEL CHARACTERISTICS, CELL SEEDING DENSITIES, AND MEDIA REPLENISHMENT. ORGANOID SIZE, MORPHOLOGY, NEURAL MATURATION, AND HEALTH WILL BE ASSESSED USING MICROSCOPY AND IMMUNOLOGIC AND MOLECULAR METHODS AND WILL YIELD POTENTIAL BIOMARKERS FOR FUTURE STUDIES; AND 3) COMPARE THE INFLAMMATORY CYTOKINE RESPONSE TO LIPOPOLYSACCHARIDE (LPS) MICROGLIAL ACTIVATION IN THE NEURAL ORGANOID SYSTEM TO THE RESPONSE GENERATED BY MICROGLIA IN ISOLATION IN A 2-DIMENSIONAL (2D) CULTURE SYSTEM. COMPLETION OF THIS STUDY WILL RESULT IN A HYDROGEL COMPOSITION AND CULTURING PROTOCOLS TO SUPPORT THE FORMATION OF REPRODUCIBLE BRAIN ORGANOIDS IN MEDIUM-THROUGHPUT TOXICOLOGY SCREENING APPLICATIONS. PHASE II STUDIES WILL UTILIZE DATA FROM PHASE I TRANSCRIPT EXPRESSION ANALYSES TO IDENTIFY QUANTITATIVE MOLECULAR PANELS TO ASSESS TOXICITY AND DEVELOP PHENOTYPIC SCREENS THAT WILL BE USED TO VALIDATE THESE ASSAYS WITH KNOWN DEVELOPMENTAL NEURAL TOXINS AND NON-TOXIC CONTROLS. THIS WORK WILL DEVELOP MORE ACCURATE MODELS FOR NEURAL HEALTH AND PATHOGENESIS AND ULTIMATELY LEAD TO COMMERCIALLY AVAILABLE ASSAYS FOR SCREENING APPLICATIONS.
$0
11/6/20
Not listed
HYDROGEL-ENABLED SELF-ASSEMBLED HUMAN BRAIN ORGANOIDS FOR DEVELOPMENTAL NEUROTOXICITY APPLICATIONS - PROJECT SUMMARY/ABSTRACT THERE IS A WELL-RECOGNIZED NEED FOR MORE ACCURATE AND COST-EFFECTIVE TOXICOLOGY SCREENING FOR THERAPEUTIC AND ENVIRONMENTAL COMPOUNDS. CURRENT METHODS USING CELL CULTURES OR ANIMAL MODELS LACK PREDICTABILITY AND CAN BE COSTLY. RECENT ADVANCES IN THE DEVELOPMENT OF STEM-CELL DERIVED BRAIN-ORGANOIDS HAVE LED TO INCREASING INTEREST IN THESE MODELS FOR NEURAL TOXICOLOGY SCREENING AS WELL AS FOR DRUG SCREENING AND THE STUDY OF NEURAL DEVELOPMENTAL MECHANISMS. HOWEVER, BECAUSE OF THEIR COST, COMPLEXITY, AND WORKFLOW REQUIREMENTS, THESE METHODS HAVE YET TO BE EFFECTIVELY IMPLEMENTED BEYOND RESEARCH APPLICATIONS. CURRENTLY NEURAL ORGANOIDS ARE TYPICALLY FORMED ON A COMPLEX EXTRACELLULAR-MATRIX DERIVED FROM TUMORS CULTURED IN RODENTS (COMMONLY KNOWN AS MATRIGEL). THE PROCESS IS CUMBERSOME, MAKES INTERROGATION DIFFICULT, AND LACKS REPRODUCIBILITY. MORE RECENTLY, INVESTIGATORS, INCLUDING A STEM PHARM COFOUNDER, HAVE DEMONSTRATED THAT COMPLEX NEURAL ORGANOIDS CAN BE FORMED, CULTURED, AND ASSAYED REPRODUCIBLY IN A PLATE-BASED SYSTEM ON ENGINEERED HYDROGEL SUBSTRATES WITH HUMAN EMBRYONIC STEM (ES) CELL-DERIVED PRECURSOR CELLS. WORK IN THIS PROPOSAL WILL FURTHER THAT DEVELOPMENT AND LEAD TO THE VALIDATION OF AN IPSC-DERIVED NEURAL ORGANOID THAT CAN BE SELF-ASSEMBLED AND CULTURED ON STEM PHARM'S SPECIALIZED SYNTHETIC HYDROGEL IN A 96-WELL PLATE FORMAT THAT IS AMENABLE TO AUTOMATED SCREENING APPLICATIONS. SPECIFIC AIMS WILL 1) VALIDATE IPSC-DERIVED HUMAN NEURAL ORGANOIDS FORMED ON STEM PHARM SYNTHETIC HYDROGELS UTILIZING NEURAL PROGENITORS AS WELL AS VASCULAR AND MICROGLIAL CELLS; 2) TRANSITION THE ORGANOID FORMATION, GROWTH, AND INTERROGATION TO A 96-WELL PLATE FORMAT. THIS WILL REQUIRE EXPERIMENTATION AND OPTIMIZATION OF HYDROGEL CHARACTERISTICS, CELL SEEDING DENSITIES, AND MEDIA REPLENISHMENT. ORGANOID SIZE, MORPHOLOGY, NEURAL MATURATION, AND HEALTH WILL BE ASSESSED USING MICROSCOPY AND IMMUNOLOGIC AND MOLECULAR METHODS AND WILL YIELD POTENTIAL BIOMARKERS FOR FUTURE STUDIES; AND 3) COMPARE THE INFLAMMATORY CYTOKINE RESPONSE TO LIPOPOLYSACCHARIDE (LPS) MICROGLIAL ACTIVATION IN THE NEURAL ORGANOID SYSTEM TO THE RESPONSE GENERATED BY MICROGLIA IN ISOLATION IN A 2-DIMENSIONAL (2D) CULTURE SYSTEM. COMPLETION OF THIS STUDY WILL RESULT IN A HYDROGEL COMPOSITION AND CULTURING PROTOCOLS TO SUPPORT THE FORMATION OF REPRODUCIBLE BRAIN ORGANOIDS IN MEDIUM-THROUGHPUT TOXICOLOGY SCREENING APPLICATIONS. PHASE II STUDIES WILL UTILIZE DATA FROM PHASE I TRANSCRIPT EXPRESSION ANALYSES TO IDENTIFY QUANTITATIVE MOLECULAR PANELS TO ASSESS TOXICITY AND DEVELOP PHENOTYPIC SCREENS THAT WILL BE USED TO VALIDATE THESE ASSAYS WITH KNOWN DEVELOPMENTAL NEURAL TOXINS AND NON-TOXIC CONTROLS. THIS WORK WILL DEVELOP MORE ACCURATE MODELS FOR NEURAL HEALTH AND PATHOGENESIS AND ULTIMATELY LEAD TO COMMERCIALLY AVAILABLE ASSAYS FOR SCREENING APPLICATIONS.
$0
11/6/20
Not listed
HYDROGEL-ENABLED SELF-ASSEMBLED HUMAN BRAIN ORGANOIDS FOR DEVELOPMENTAL NEUROTOXICITY APPLICATIONS
$225.0k
5/10/19